Terms: = Uterine cancer AND POLE, POLE1, 5426, FLJ21434, DKFZp434F222, ENSG00000177084 AND Treatment
126 results:
1. FIGO 2023 endometrial staging: a leap of faith into the new "prognostic based' rather than "anatomical based" staging-too fast too furious??
Bassetty KC; Begum D; Barmon D; Baruah U; Gupta S; Kumar M; Nath J; Khanikar D; Bhattacharyya M; Roy PS
J Cancer Res Clin Oncol; 2024 May; 150(5):251. PubMed ID: 38733417
[TBL] [Abstract] [Full Text] [Related]
2. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer.
D'Agostino E; Mastrodomenico L; Ponzoni O; Baldessari C; Piombino C; Pipitone S; Giuseppa Vitale M; Sabbatini R; Dominici M; Toss A
Cancer Treat Rev; 2024 May; 126():102723. PubMed ID: 38555857
[TBL] [Abstract] [Full Text] [Related]
3. Can Endometrial Cytology Identify Patients Who Would Benefit from Immunotherapy?
Yanazume S; Kirita Y; Kobayashi Y; Kitazono I; Akahane T; Mizuno M; Togami S; Tanimoto A; Kobayashi H
Acta Cytol; 2024; 68(2):128-136. PubMed ID: 38471464
[TBL] [Abstract] [Full Text] [Related]
4. Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer.
Luzarraga Aznar A; Bebia V; López-Gil C; Villafranca-Magdalena B; Salazar-Huayna L; Castellvi J; Colàs E; Gil-Moreno A; Cabrera S
Int J Gynecol Cancer; 2024 May; 34(5):659-666. PubMed ID: 38378696
[TBL] [Abstract] [Full Text] [Related]
5. Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.
Lindemann K; Kildal W; Kleppe A; Tobin KAR; Pradhan M; Isaksen MX; Vlatkovic L; Danielsen HE; Kristensen GB; Askautrud HA
Eur J Cancer; 2024 Mar; 200():113584. PubMed ID: 38330767
[TBL] [Abstract] [Full Text] [Related]
6. New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere.
Bruchim I; Capasso I; Polonsky A; Meisel S; Salutari V; Werner H; Lorusso D; Scambia G; Fanfani F
Expert Opin Ther Targets; 2024; 28(1-2):29-43. PubMed ID: 38327111
[TBL] [Abstract] [Full Text] [Related]
7. Integration of the Molecular Classification of Endometrial Carcinoma to Select Patients for Fertility Sparing Strategies.
Bani MA; Maulard A; Morice P; Chargari C; Genestie C
Anticancer Res; 2024 Feb; 44(2):445-452. PubMed ID: 38307584
[TBL] [Abstract] [Full Text] [Related]
8. Exploring Co-occurring pole Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
[TBL] [Abstract] [Full Text] [Related]
9. The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway.
Tang M; Yin S; Zeng H; Huang A; Huang Y; Hu Z; Shah AR; Zhang S; Li H; Chen G
Cell Death Dis; 2024 Jan; 15(1):69. PubMed ID: 38238314
[TBL] [Abstract] [Full Text] [Related]
10. Race, Prevalence of pole and POLD1 Alterations, and Survival Among Patients With Endometrial cancer.
Zheng S; Donnelly ED; Strauss JB
JAMA Netw Open; 2024 Jan; 7(1):e2351906. PubMed ID: 38231514
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.
Lv X; Guo L; Wang C
J Gynecol Oncol; 2024 May; 35(3):e27. PubMed ID: 38216133
[TBL] [Abstract] [Full Text] [Related]
12. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
13. Characteristics and outcomes of surgically staged multiple classifier endometrial cancer.
Bogani G; Betella I; Multinu F; Casarin J; GhezzI F; Sorbi F; VizziellI G; Petrillo M; Cianci S; Berretta R; PaolinI B; FanfanI F; De Vitis L; Scambia G; Mariani A; Colombo N; Raspagliesi F
Eur J Surg Oncol; 2024 Jan; 50(1):107269. PubMed ID: 37984242
[TBL] [Abstract] [Full Text] [Related]
14. Molecular-based classification of endometrial carcinoma in Northern Thailand: impact on prognosis and potential for implementation in resource-limited settings.
Dankai W; Pongsuvareeyakul T; Phinyo P; Tejamai C; Teerapakpinyo C; Cheewakriangkrai C; Lekawanvijit S; Siriaunkgul S; Khunamornpong S
BMC Womens Health; 2023 Nov; 23(1):605. PubMed ID: 37964201
[TBL] [Abstract] [Full Text] [Related]
15. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S
JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058
[TBL] [Abstract] [Full Text] [Related]
16. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated pole variants.
Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
[TBL] [Abstract] [Full Text] [Related]
17. Machine learning endometrial cancer risk prediction model: integrating guidelines of European Society for Medical Oncology with the tumor immune framework.
Bruno V; Betti M; D'Ambrosio L; Massacci A; Chiofalo B; Pietropolli A; Piaggio G; Ciliberto G; Nisticò P; Pallocca M; Buda A; Vizza E
Int J Gynecol Cancer; 2023 Nov; 33(11):1708-1714. PubMed ID: 37875322
[TBL] [Abstract] [Full Text] [Related]
18. [Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles].
Shao WY; Dong YT; Lyu QY; Liao JB; Xue Y; Chen XJ
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):742-754. PubMed ID: 37849255
[No Abstract] [Full Text] [Related]
19. [Risk factor analysis of lymph node metastasis in endometrial carcinoma combined with molecular types].
Li LL; Li H; Li J; Zhang XB; Wang ZQ; Shen DH; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):733-741. PubMed ID: 37849254
[No Abstract] [Full Text] [Related]
20. PErsonalized treatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.
Loukovaara M; Bützow R; Staff S; Mäenpää M; Faltinová M; Lassus H; Veijalainen O; Grönvall M; Vaalavirta L; Kuikka E; Haataja M; Urpilainen E; Simojoki M; Anttila M; Auranen A
Int J Gynecol Cancer; 2023 Nov; 33(11):1807-1811. PubMed ID: 37813479
[TBL] [Abstract] [Full Text] [Related]
[Next]